Tissue factor pathway inhibitor anticoagulant activity: Risk for venous thrombosis and effect of hormonal state

British Journal of Haematology

Volumn 132, Issue 3, 2006, Pages 333-338

  Dahm, Anders ^a   R Rosendaal, Frits ^b   Andersen, Trine O ^a   Sandset, Per M ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Deep vein thrombosis; Diluted prothrombin time; Thrombophilia; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

TISSUE FACTOR PATHWAY INHIBITOR; ANTICOAGULANT AGENT; ANTIGEN; BLOOD CLOTTING FACTOR 10A; HORMONE; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; ORAL CONTRACEPTIVE AGENT;

ANTICOAGULATION; ARTICLE; BIOASSAY; BLOOD SAMPLING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS; AGED; BLOOD; CASE CONTROL STUDY; DRUG ANTAGONISM; MENOPAUSE; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK;

AGED; ANTICOAGULANTS; ANTIGENS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FACTOR XA; FEMALE; HORMONES; HUMANS; LIPOPROTEINS; MALE; MENOPAUSE; ODDS RATIO; PROTHROMBIN TIME; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33644853425     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05876.x     Document Type: Article

References (29)

1. Ariens R.A. 2005 The quest for the Holy Grail of tissue factor pathway inhibitor deficiency has just begun Journal of Thrombosis and Haemostasis 3 649 650
2. Bajaj M.S. Bajaj S.P. 1997 Tissue factor pathway inhibitor: potential therapeutic applications Thrombosis and Haemostasis 78 471 477
3. Bendz B. Andersen T.O. Sandset P.M. 2000 A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1 Thrombosis Research 97 463 472
4. Dahm A. van Hylckama Vlieg A. Bendz B. Rosendaal F. Bertina R.M. Sandset P.M. 2003 Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis Blood 101 4387 4392
5. Dahm A.E. Andersen T.O. Rosendaal F. Sandset P.M. 2005 A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI) Journal of Thrombosis and Haemostasis 3 651 658
6. Hansen J.B. Huseby N.E. Sandset P.M. Svensson B. Lyngmo V. Nordoy A. 1994 Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma Arteriosclerosis and Thrombosis 14 223 229
7. Hansen J.B. Huseby K.R. Huseby N.E. Sandset P.M. Hanssen T.A. Nordoy A. 1995 Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia Arteriosclerosis Thrombosis and Vascular Biology 15 879 885
8. Hansen J.B. Huseby K.R. Huseby N.E. Ezban M. Nordoy A. 1997 Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro Thrombosis Research 85 413 425
9. Harris G.M. Stendt C.L. Vollenhoven B.J. Gan T.E. Tipping P.G. 1999 Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives American Journal of Hematology 60 175 180
10. Hoibraaten E. Qvigstad E. Andersen T.O. Mowinckel M.C. Sandset P.M. 2001 The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism - results from a randomized, double-blind, clinical trial Thrombosis and Haemostasis 85 775 781
11. Holst J. Lindblad B. Bergqvist D. Nordfang O. Ostergaard P.B. Petersen J.L. Nielsen G. Hedner U. 1993 Antithrombotic properties of a truncated recombinant tissue factor pathway inhibitor in an experimental venous thrombosis model Haemostasis 23 Suppl. 1 112 117
12. Huang Z.F. Wun T.C. Broze G. 1993 Kinetics of factor Xa inhibition by tissue factor pathway inhibitor Journal of Biological Chemistry 268 26950 26955
13. Huang Z.F. Higuchi D. Lasky N. Broze G. 1997 Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice Blood 90 944 951
14. van Hylckama Vlieg A. van der Linden I.K. Bertina R.M. Rosendaal F.R. 2000 High levels of factor IX increase the risk of venous thrombosis Blood 95 3678 3682
15. Kaiser B. Fareed J. 1996 Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis Thrombosis and Haemostasis 76 615 620
16. Koster T. Rosendaal F.R. de Ronde H. Briet E. Vandenbroucke J.P. Bertina R.M. 1993 Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study Lancet 342 1503 1506
17. Lindahl A.K. Jacobsen P.B. Sandset P.M. Abildgaard U. 1991 Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients Blood Coagulation and Fibrinolysis 2 713 721
18. Lindahl A.K. Sandset P.M. Abildgaard U. 1992 The present status of tissue factor pathway inhibitor Blood Coagulation and Fibrinolysis 3 439 449
19. Lindhout T. Willems G. Blezer R. Hemker H.C. 1994 Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor Biochemical Journal 297 Pt 1 131 136
20. Lindhout T. Franssen J. Willems G. 1995 Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor Thrombosis and Haemostasis 74 910 915
21. Lockett J.M. Mast A.E. 2002 Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor Biochemistry 41 4989 4997
22. Morange P.E. Simon C. Alessi M.C. Luc G. Arveiler D. Ferrieres J. Amouyel P. Evans A. Ducimetiere P. Juhan-Vague I. 2004 Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study Circulation 109 1343 1348
23. Nordfang O. Bjorn S.E. Valentin S. Nielsen L.S. Wildgoose P. Beck T.C. Hedner U. 1991 The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity Biochemistry 30 10371 10376
24. Novotny W.F. Girard T.J. Miletich J.P. Broze G. 1989 Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma Journal of Biological Chemistry 264 18832 18837
25. Sandset P.M. Bendz B. 1997 Tissue factor pathway inhibitor: clinical deficiency states Thrombosis and Haemostasis 78 467 470
26. Sandset P.M. Warn-Cramer B.J. Maki S.L. Rapaport S.I. 1991a Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction Blood 78 1496 1502
27. Sandset P.M. Warn-Cramer B.J. Rao L.V. Maki S.L. Rapaport S.I. 1991b Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant Proceedings of the National Academy of Sciences of the United States of America 88 708 712
28. Sandset P.M. Bendz B. Hansen J.B. 2000 Physiological function of tissue factor pathway inhibitor and interaction with heparins Haemostasis 30 Suppl. 2 48 56
29. de Visser M.C. van Hylckama Vlieg A. Tans G. Rosing J. Dahm A.E. Sandset P.M. Rosendaal F.R. Bertina R.M. 2005 Determinants of the APTT- and ETP-based APC sensitivity tests Journal of Thrombosis and Haemostasis 3 1488 1494